| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Skibsted Russell is a Chief Financial Officer at LCTX, with reported holdings spanning 2 companies. Recent filings cover 8 purchases and 0 sales. Those positions are worth an estimated $57K at current prices.
Skibsted Russell's largest disclosed position is in PCSA as Chief Financial Officer, worth about $32K. Net of sales, the recent Form 4 record there shows accumulation of 16,705 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 3,277 | $1.93 | $6,324.61 | +24.4% | -4.2% | - | |
| Jun 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 2,654 | $2.22 | $5,891.88 | +24.7% | -14.9% | - | |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 2,292 | $2.57 | $5,890.44 | +27.1% | -17.6% | - | |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 1,984 | $2.97 | $5,892.48 | +30.6% | -15.5% | - | |
| Apr 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 2,190 | $2.69 | $5,891.10 | +50.8% | -24.8% | - | |
| Apr 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 1,984 | $2.97 | $5,892.48 | +85.4% | -22.6% | - | |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 2,324 | $2.54 | $5,891.34 | New | -23.2% | - | |
| Aug 23, 2017 | LCTX Lineage Cell Therapeutics, Inc. | Chief Financial Officer | Buy | 2,000 | $2.64 | $5,284.80 | New | - | - |